Plain-English translation of NCT07397455 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a research study where healthy vaccinated adults will be deliberately exposed to a small amount of the SARS-CoV-2 Omicron EG.5.1 variant through nasal drops. The goal is to understand how this virus infects vaccinated people and causes mild (or no) symptoms, so researchers can develop better vaccines and treatments in the future. You would stay in a quarantine facility for about 10–12 days while doctors monitor your health closely.
Scientists need to understand how newer COVID variants behave in vaccinated people to create improved vaccines and treatments. This controlled study allows researchers to safely study infection patterns in a way that wouldn't be possible otherwise.
You likely qualify if…
You likely don't qualify if…
You'll receive the virus exposure as nasal drops on day one, then stay in a quarantine unit at a facility in Oxford or London for approximately 10–12 days. During your stay, doctors will regularly swab your nose and throat, take blood samples, and check your symptoms to track how you respond to the infection. After you leave quarantine, the study team will follow up with you for 6 months to monitor your long-term health and immune response.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
United Kingdom